Fasting glucose
Decrease · moderate
Improves insulin sensitivity
Literature evidence
Compound library
Vivy evidence dossier
MOTS-c
Also indexed as MOTS-c, MOTS-c peptide
T3Peptides
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life4 hr
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
Fasting insulin
Decrease · moderate
Improves insulin signaling
Literature evidence
HOMA-IR
Decrease · moderate
Improves insulin sensitivity
Literature evidence
Triglycerides
Decrease · small
Improves lipid metabolism
Literature evidence
Adiponectin
Increase · small
Enhances metabolic signaling
Literature evidence
CRP
Decrease · small
Anti-inflammatory effects
Literature evidence
AMPK activity
Increase · moderate
Activates AMPK metabolic pathway
Literature evidence
Body fat
Decrease · small
Improves metabolic rate
Literature evidence
Leptin
Decrease · small
Improves leptin sensitivity
Literature evidence
Weight
Decrease · small
Improves metabolic rate
Literature evidence
Mitochondrial biogenesis
Increase · small
Promotes mitochondrial turnover
Literature evidence
LDL cholesterol
Decrease · small
Improves lipid profile
Literature evidence
Systolic blood pressure
Decrease · small
Metabolic improvements
Literature evidence
Exercise tolerance
Increase · small
Improves metabolic efficiency
Literature evidence
Keep in view
Safety discussion points
MOTS-c is a mitochondrial-derived peptide (16 amino acids) that acts as an exercise mimetic and metabolic regulator. Investigational. Not FDA-approved.
Keep the reference close
Track MOTS-c in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.